Genomiconomics.com
Executive Summary
With the free-fall in dot com stocks, money has flowed--with a vengeance--into biotech. But the valuations are not sustainable: most of the new companies are shooting for a market far too small to support even half of the new competitors, and trying to sell only portions of what drug companies want to buy.
You may also be interested in...
Aurobindo Upbeat On Outlook, Transfers Biologics Biz
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.
Some Annex XVI Products Likely To Be Delayed, Latest Commission Updated Rolling Plan Suggests
The European Commission has updated its rolling plan. It now looks as if current member state rules for non-medical products could persist beyond the 26 May 2021 deadline.
GSK Tapping Into Naturals Trend With UK Piri Extension
GSK launches a 100% natural saline spray in the UK to compliment its Piri hayfever brand portfolio.
Need a specific report? 1000+ reports available
Buy Reports